Efficacy and safety of seladelpar vs placebo in patients with primary biliary cholangitis and metabolic syndrome in the pivotal phase 3 RESPONSE study
M J Mayo, E J Lawitz, A M Villamil, E Janczewska et autres
0 citationsZeitschrift für Gastroenterologie